Chimerix is actively seeking opportunities to collaborate in order to increase innovation and efficiencies to help speed the development of potential life-saving medicines to patients while creating long-term value. With a focus on extending patients’ lives who are suffering from life-threatening diseases, we have specific interest in partnering for clinical-stage assets in oncology and biodefense where we can leverage our substantial expertise. For more information about our interests and how we might work together to advance innovation, please contact Mike Andriole, Chief Business Officer, at

Key benefits of collaborating with Chimerix include:

  • Strong culture of execution
  • Extensive clinical development and regulatory experience
  • Creativity in constructing partnerships
  • Commitment to professional alliance management
  • Public company infrastructure

Oncology Collaborations

Cantex Pharmaceuticals

In July 2019, Chimerix announced exclusive worldwide rights to develop and commercialize CX-01 (also known as dociparstat, or DSTAT) in acute myeloid leukemia (AML). Read the announcement here.

Biodefense Collaborations


In 2011, Chimerix initiated a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir (BCV) as a medical countermeasure to treat smallpox outbreaks due to a bioterror event or accidental release. Brincidofovir has received Fast Track Designation and Orphan Drug Designation from the FDA for smallpox.

Other Collaborations

SymBio Pharmaceuticals

In Sept. 2019, Chimerix announced a global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop, manufacture and commercialize BCV in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing associated with BCV in its licensed indications. Read the announcement here.